Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? the case for rabeprazole

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 10, 2011, Pages 845-851

  Pace, Fabio ^a   Coudsy, Bogdana ^d   Delemos, Byron ^e   Sun, Yijun ^f   Xiang, Jim ^e   Lococo, John ^e   Casalini, Stefania ^b   Li, Honglan ^f   Pelosini, Iva ^c   Scarpignato, Carmelo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Janssen Cilag SpA Italia   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Medical Department   (France)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f EISAI INC   (United States)

Author keywords

body mass index; erosive esophagitis; obesity; proton pump inhibitors; rabeprazole

Indexed keywords

OMEPRAZOLE; RABEPRAZOLE;

ARTICLE; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESOPHAGUS MUCOSA; HEALING; HEARTBURN; HUMAN; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; BODY MASS INDEX; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OBESITY; OMEPRAZOLE; OVERWEIGHT; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WOUND HEALING;

EID: 80052658924     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834991b7     Document Type: Article

References (38)

1. World Health Organization. Obesity and overweight. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/index.html [Accessed on 19 October 2007].
2. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/nhanes/nhanes- questionnaires.htm. [Accessed on 5 June 2007].
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.
4. NIH, NHLBI Obesity Education Initiative. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf. [Accessed on 5 June 2007].
5. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-430. (Pubitemid 32049639)
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348:1625-1638. (Pubitemid 36459468)
7. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101:2619-2628. (Pubitemid 44665262)
8. Cremonini F, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. Neurogastroenterol Motil 2006; 18:987-994. (Pubitemid 44571650)
9. Hampel H, Abraham N, El-Serag H. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143:199-211. (Pubitemid 41076753)
10. Jacobson BC, Somers SC, Fuchs CF, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354:2340-2348. (Pubitemid 43801279)
11. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100:1243-1250. (Pubitemid 40904344)
12. Veugelers PJ, Porter GA, Guernsey DL, Casson AG. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006; 19:321-328. (Pubitemid 44390435)
13. Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006; 130:639-649. (Pubitemid 43374513)
14. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999; 94:2840-2844. (Pubitemid 29482744)
15. Wu AH, Tseng C-C, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003; 98:940-948. (Pubitemid 37022093)
16. Fisher BL, Pennathur A, Mutnick JL, Little AG. Obesity correlates with gastroesophageal reflux. Dig Dis Sci 1999; 44:2290-2294.
17. Wu JC, Mui LM, Cheung CM, Chan Y, Sung JJ. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007; 132:883-889. (Pubitemid 46440865)
18. El-Serag HB, Tran T, Richardson P, Ergun G. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 2006; 41:887-891. (Pubitemid 43995463)
19. Quiroga E, Cuenca-Abente F, Flum D, Dellinger EP, Oelschlager BK. Impaired esophageal function in morbidly obese patients with gastroesophageal reflux disease: evaluation with multichannel intraluminal impedance. Surg Endosc 2006; 20:739-743. (Pubitemid 43978771)
20. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Three-to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33:1016-1022. (Pubitemid 28505642)
21. Talley NJ, Armstrong D, Junghard O, Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24:371-376. (Pubitemid 43972905)
22. Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, et al.; Italian Rabeprazole Study Group. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis 2005; 37:741-450.
23. Jacobson BC, DeLemos B, Sun Y, Xian J, LoCoco J, Li H, et al. Efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg versus omeprazole (OME) 20 mg. Am J Gastroenterol 2007; 102 (Suppl 2): S150.
24. Bruley Des Varannes S, Ducrotté P, Xiang J, Sun Y, Lococo J, Coudsy B, et al. Is BMI associated with pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in GERD patients. Gut 2009; 58 (Suppl II):A279.
25. Jacobson BC, DeLemos B, Sun Y, Xian J, LoCoco J, Li H, et al. Treatment outcomes with rabeprazole (RAB) 20 mg versus placebo (PBO) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of 2 US multicenter trials. Gastroenterology 2007; 132 (Suppl 2):A493.
26. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005; 50:2009-2018. (Pubitemid 41504082)
27. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39:215-231.
28. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49:71-87.
29. Weir MR. Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991; 90 (Suppl 5A):3S-14S.
30. Anonimous. Body surface area for adjustment of drug dose. Drug Ther Bull 2010; 48:33-36.
31. Sheu BS, Chang WL, Cheng HC, Kao AW, Lu CC. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. Am J Gastroenterol 2008; 103:2209-2214.
32. Sheu BS, Cheng HC, Chang WL, Chen WY, Kao AW. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007; 102:2387-2394.
33. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37:8-19. (Pubitemid 29043392)
34. Schelbert KB. Comorbidities of obesity. Prim Care 2009; 36:271-285.
35. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:88.
36. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13 (Suppl 3): 18-26. (Pubitemid 29389408)
37. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13:611-616. (Pubitemid 32466269)
38. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 57:595-601. (Pubitemid 35025465)